B of A Securities Downgrades Beam Therapeutics to Neutral, Announces $35 Price Target
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Greg Harrison downgraded Beam Therapeutics (NASDAQ:BEAM) from Buy to Neutral and set a price target of $35.
December 15, 2023 | 1:37 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Beam Therapeutics was downgraded by B of A Securities from Buy to Neutral with a price target of $35.
Downgrades by analysts can lead to a negative perception among investors and potentially cause a short-term decline in the stock's price. The new price target of $35 may also set investor expectations on the stock's value.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100